# Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids

> **NCT05568940** · — · WITHDRAWN · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre**

## Conditions studied

- Endometriosis
- Fibroids

## Interventions

- **DRUG:** Tibolone 2.5 Mg Oral Tablet

## Key facts

- **NCT ID:** NCT05568940
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-09
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** More critical projects were prioritized.
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05568940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05568940, "Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05568940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*